Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.

Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, Botros FT

The lancet. Diabetes & endocrinology14 Jun 2018Cited by 506 (Europe PMC)

PMID29910024DOI10.1016/s2213-8587(18)30104-9PepBankPUB-29910024

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

16 results from studies that gave the peptide. 16 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with T2D and chronic kidney disease, dulaglutide 1.5 mg was non-inferior to insulin glargine for HbA1c reduction.
In plain wordsIn patients with T2D and kidney disease, dulaglutide 1.5 mg met the non-inferiority criterion versus insulin glargine for HbA1c reduction.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedHbA1c change at 26 weeks
Study
n = 183
Comparator
Insulin glargine
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.2%
dulaglutide 1.5 mg
HbA1c change
−1.1%
insulin glargine, 26 weeks
HbA1c difference versus insulin glargine
−0.05%
dulaglutide 1.5 mg minus insulin glargine, 26 weeks
Source sentences
Summary
The effects on HbA_1c change at 26 weeks of dulaglutide 1·5 mg and 0·75 mg were non-inferior to those of insulin glargine (least squares mean [LSM] -1·2% [SE 0·1] with dulaglutide 1·5 mg [183 patients]
Summary
-1·1% [0·1] with insulin glargine [186 patients]
2 context sentences(design, population, supporting numbers)
Summary · context
The differences in HbA_1c concentration at 26 weeks between dulaglutide and insulin glargine treatments were LSM difference -0·05% (95% CI -0·26 to 0·15, p<0·0001) with dulaglutide 1·5 mg and 0·02% (-0·18 to -0·22, p=0·0001) with dulaglutide 0·75 mg.
Summary · context
Participants were randomly assigned (1:1:1) by use of a computer-generated random sequence with an interactive response system to once-weekly injectable dulaglutide 1·5 mg, once-weekly dulaglutide 0·75 mg, or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks.
Report a problemFND-2991002401
02HumanRandomized controlled trialEfficacy outcome
In patients with T2D and chronic kidney disease, dulaglutide 0.75 mg was non-inferior to insulin glargine for HbA1c reduction.
In plain wordsIn patients with T2D and kidney disease, dulaglutide 0.75 mg met the non-inferiority criterion versus insulin glargine for HbA1c reduction.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedHbA1c change at 26 weeks
Study
n = 180
Comparator
Insulin glargine
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg weekly · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.1%
dulaglutide 0.75 mg
HbA1c change
−1.1%
insulin glargine, 26 weeks
HbA1c difference versus insulin glargine
0.02%
dulaglutide 0.75 mg minus insulin glargine, 26 weeks
Source sentences
Summary
-1·1% [0·1] with dulaglutide 0·75 mg [180 patients]
Summary
-1·1% [0·1] with insulin glargine [186 patients]
3 context sentences(design, population, supporting numbers)
Summary · context
The effects on HbA_1c change at 26 weeks of dulaglutide 1·5 mg and 0·75 mg were non-inferior to those of insulin glargine
Summary · context
The differences in HbA_1c concentration at 26 weeks between dulaglutide and insulin glargine treatments were LSM difference -0·05% (95% CI -0·26 to 0·15, p<0·0001) with dulaglutide 1·5 mg and 0·02% (-0·18 to -0·22, p=0·0001) with dulaglutide 0·75 mg.
Summary · context
Participants were randomly assigned (1:1:1) by use of a computer-generated random sequence with an interactive response system to once-weekly injectable dulaglutide 1·5 mg, once-weekly dulaglutide 0·75 mg, or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks.
Report a problemFND-2991002402
03HumanRandomized controlled trialEfficacy outcome
In patients with T2D and chronic kidney disease, eGFR was higher with dulaglutide 1.5 mg than insulin glargine.
In plain wordsIn patients with T2D and kidney disease, kidney filtration was higher with dulaglutide 1.5 mg than insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseeGFR
Study
n: not reported in source
Comparator
Insulin glargine
Analysis
Secondary
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.5 mg weekly · 52 weeksAs given in this study (human).
Measurements
eGFR (CKD-EPI cystatin C, geometric LSM)
34 mL/min per 1.73 m²
dulaglutide 1.5 mg, 52 weeks
eGFR (CKD-EPI cystatin C, geometric LSM)
31.3 mL/min per 1.73 m²
insulin glargine, 52 weeks
Source sentences
Summary
At 52 weeks, eGFR was higher with dulaglutide 1·5 mg (Chronic Kidney Disease Epidemiology Collaboration equation by cystatin C geometric LSM 34·0 mL/min per 1·73 m² [SE 0·7]; p=0·005 vs insulin glargine)
Summary
than with insulin glargine (31·3 mL/min per 1·73 m² [0·7]).
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomly assigned (1:1:1) by use of a computer-generated random sequence with an interactive response system to once-weekly injectable dulaglutide 1·5 mg, once-weekly dulaglutide 0·75 mg, or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks.
Report a problemFND-2991002405
04HumanRandomized controlled trialEfficacy outcome
In patients with T2D and chronic kidney disease, eGFR was higher with dulaglutide 0.75 mg than insulin glargine.
In plain wordsIn patients with T2D and kidney disease, kidney filtration was higher with dulaglutide 0.75 mg than insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseeGFR
Study
n: not reported in source
Comparator
Insulin glargine
Analysis
Secondary
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.75 mg weekly · 52 weeksAs given in this study (human).
Measurements
eGFR (CKD-EPI cystatin C, geometric LSM)
33.8 mL/min per 1.73 m²
dulaglutide 0.75 mg, 52 weeks
eGFR (CKD-EPI cystatin C, geometric LSM)
31.3 mL/min per 1.73 m²
insulin glargine, 52 weeks
Source sentences
Summary
and dulaglutide 0·75 mg (33·8 mL/min per 1·73 m² [0·7]; p=0·009 vs insulin glargine) than with insulin glargine (31·3 mL/min per 1·73 m² [0·7]).
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomly assigned (1:1:1) by use of a computer-generated random sequence with an interactive response system to once-weekly injectable dulaglutide 1·5 mg, once-weekly dulaglutide 0·75 mg, or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks.
Report a problemFND-2991002406
05HumanRandomized controlled trialEfficacy outcome
In patients with T2D and chronic kidney disease, UACR reduction with dulaglutide 1.5 mg did not differ significantly from insulin glargine.
In plain wordsIn patients with T2D and kidney disease, urinary albumin reduction with dulaglutide 1.5 mg did not differ significantly from insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeUACR reduction
Study
n: not reported in source
Comparator
Insulin glargine
Analysis
Secondary
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.5 mg weekly · 52 weeksAs given in this study (human).
Measurements
UACR change
−22.5%
dulaglutide 1.5 mg
UACR change
−13%
insulin glargine, 52 weeks
Source sentences
Summary
At 52 weeks, the effects of dulaglutide 1·5 mg and 0·75 mg on UACR reduction were not significantly different from that of insulin glargine (LSM -22·5% [95% CI -35·1 to -7·5] with dulaglutide 1·5 mg; -20·1% [-33·1 to -4·6] with dulaglutide 0·75 mg; -13·0% [-27·1 to 3·9] with insulin glargine).
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomly assigned (1:1:1) by use of a computer-generated random sequence with an interactive response system to once-weekly injectable dulaglutide 1·5 mg, once-weekly dulaglutide 0·75 mg, or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks.
Report a problemFND-2991002407
06HumanRandomized controlled trialEfficacy outcome
In patients with T2D and chronic kidney disease, UACR reduction with dulaglutide 0.75 mg did not differ significantly from insulin glargine.
In plain wordsIn patients with T2D and kidney disease, urinary albumin reduction with dulaglutide 0.75 mg did not differ significantly from insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeUACR reduction
Study
n: not reported in source
Comparator
Insulin glargine
Analysis
Secondary
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.75 mg weekly · 52 weeksAs given in this study (human).
Measurements
UACR change
−20.1%
dulaglutide 0.75 mg
UACR change
−13%
insulin glargine, 52 weeks
Source sentences
Summary
At 52 weeks, the effects of dulaglutide 1·5 mg and 0·75 mg on UACR reduction were not significantly different from that of insulin glargine (LSM -22·5% [95% CI -35·1 to -7·5] with dulaglutide 1·5 mg; -20·1% [-33·1 to -4·6] with dulaglutide 0·75 mg; -13·0% [-27·1 to 3·9] with insulin glargine).
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomly assigned (1:1:1) by use of a computer-generated random sequence with an interactive response system to once-weekly injectable dulaglutide 1·5 mg, once-weekly dulaglutide 0·75 mg, or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks.
Report a problemFND-2991002408
07HumanRandomized controlled trialSafety outcome
In patients with T2D and kidney disease, serious adverse event proportions were similar with dulaglutide 1.5 mg and insulin glargine.
In plain wordsIn patients with T2D and kidney disease, serious adverse event proportions were similar with dulaglutide 1.5 mg and insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeSerious adverse events
Study
n = 192
Comparator
Insulin glargine
Outcome group
Adverse events · Whole body
Studied dose
1.5 mg weeklyAs given in this study (human).
Measurements
Serious adverse events
20%
dulaglutide 1.5 mg
Serious adverse events
27%
insulin glargine
Source sentences
Summary
Proportions of patients with any serious adverse events were similar across groups (20% [38 of 192] with dulaglutide 1·5 mg, 24% [45 of 190] with dulaglutide 0·75 mg, and 27% [52 of 194] with insulin glargine).
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomly assigned (1:1:1) by use of a computer-generated random sequence with an interactive response system to once-weekly injectable dulaglutide 1·5 mg, once-weekly dulaglutide 0·75 mg, or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks.
Report a problemFND-2991002409
08HumanRandomized controlled trialSafety outcome
In patients with T2D and kidney disease, nausea was more frequent with dulaglutide 1.5 mg than insulin glargine.
In plain wordsIn patients with T2D and kidney disease, nausea was more frequent with dulaglutide 1.5 mg than insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseNausea
Study
n = 192
Comparator
Insulin glargine
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.5 mg weeklyAs given in this study (human).
Measurements
Nausea
20%
dulaglutide 1.5 mg
Nausea
5%
insulin glargine
Source sentences
Summary
Dulaglutide was associated with higher rates of nausea (20% [38 of 192] with dulaglutide 1·5 mg and 14% [27 of 190] with 0·75 mg, vs 5% [nine of 194] with insulin glargine)
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomly assigned (1:1:1) by use of a computer-generated random sequence with an interactive response system to once-weekly injectable dulaglutide 1·5 mg, once-weekly dulaglutide 0·75 mg, or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks.
Report a problemFND-2991002411
09HumanRandomized controlled trialSafety outcome
In patients with T2D and kidney disease, diarrhoea was more frequent with dulaglutide 1.5 mg than insulin glargine.
In plain wordsIn patients with T2D and kidney disease, diarrhoea was more frequent with dulaglutide 1.5 mg than insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseDiarrhoea
Study
n = 192
Comparator
Insulin glargine
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.5 mg weeklyAs given in this study (human).
Measurements
Diarrhoea
17%
dulaglutide 1.5 mg
Diarrhoea
7%
insulin glargine
Source sentences
Summary
and diarrhoea (17% [33 of 192] with dulaglutide 1·5 mg and 16% [30 of 190] with 0·75 mg, vs 7% [14 of 194] with insulin glargine)
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomly assigned (1:1:1) by use of a computer-generated random sequence with an interactive response system to once-weekly injectable dulaglutide 1·5 mg, once-weekly dulaglutide 0·75 mg, or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks.
Report a problemFND-2991002413
10HumanRandomized controlled trialSafety outcome
In patients with T2D and kidney disease, symptomatic hypoglycaemia rates were lower with dulaglutide 1.5 mg than insulin glargine.
In plain wordsIn patients with T2D and kidney disease, low-blood-sugar rates were lower with dulaglutide 1.5 mg than insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseSymptomatic hypoglycaemia
Study
n = 192
Comparator
Insulin glargine
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.5 mg weeklyAs given in this study (human).
Measurements
Symptomatic hypoglycaemia
4.4 events per patient per year
dulaglutide 1.5 mg
Symptomatic hypoglycaemia
9.6 events per patient per year
insulin glargine
Source sentences
Summary
and lower rates of symptomatic hypoglycaemia (4·4 events per patient per year with dulaglutide 1·5 mg and 4·3 with dulaglutide 0·75 mg, vs 9·6 with insulin glargine).
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomly assigned (1:1:1) by use of a computer-generated random sequence with an interactive response system to once-weekly injectable dulaglutide 1·5 mg, once-weekly dulaglutide 0·75 mg, or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks.
Report a problemFND-2991002415
11HumanRandomized controlled trialSafety outcome
In patients with T2D and kidney disease, end-stage renal disease occurred in 4% with dulaglutide 1.5 mg versus 8% with insulin glargine.
In plain wordsIn patients with T2D and kidney disease, end-stage renal disease occurred in 4% with dulaglutide 1.5 mg versus 8% with insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedEnd-stage renal disease
Study
n = 192
Comparator
Insulin glargine
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.5 mg weeklyAs given in this study (human).
Measurements
End-stage renal disease
4%
dulaglutide 1.5 mg
End-stage renal disease
8%
insulin glargine
Source sentences
Summary
End-stage renal disease occurred in 38 participants: eight (4%) of 192 with dulaglutide 1·5 mg, 14 (7%) of 190 with dulaglutide 0·75 mg, and 16 (8%) of 194 with insulin glargine.
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomly assigned (1:1:1) by use of a computer-generated random sequence with an interactive response system to once-weekly injectable dulaglutide 1·5 mg, once-weekly dulaglutide 0·75 mg, or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks.
Report a problemFND-2991002417
12HumanRandomized controlled trialSafety outcome
In patients with T2D and kidney disease, serious adverse event proportions were similar with dulaglutide 0.75 mg and insulin glargine.
In plain wordsIn patients with T2D and kidney disease, serious adverse event proportions were similar with dulaglutide 0.75 mg and insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeSerious adverse events
Study
n = 190
Comparator
Insulin glargine
Outcome group
Adverse events · Whole body
Studied dose
0.75 mg weeklyAs given in this study (human).
Measurements
Serious adverse events
24%
dulaglutide 0.75 mg
Serious adverse events
27%
insulin glargine
Source sentences
Summary
Proportions of patients with any serious adverse events were similar across groups (20% [38 of 192] with dulaglutide 1·5 mg, 24% [45 of 190] with dulaglutide 0·75 mg, and 27% [52 of 194] with insulin glargine).
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomly assigned (1:1:1) by use of a computer-generated random sequence with an interactive response system to once-weekly injectable dulaglutide 1·5 mg, once-weekly dulaglutide 0·75 mg, or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks.
Report a problemFND-2991002410
13HumanRandomized controlled trialSafety outcome
In patients with T2D and kidney disease, nausea was more frequent with dulaglutide 0.75 mg than insulin glargine.
In plain wordsIn patients with T2D and kidney disease, nausea was more frequent with dulaglutide 0.75 mg than insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseNausea
Study
n = 190
Comparator
Insulin glargine
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.75 mg weeklyAs given in this study (human).
Measurements
Nausea
14%
dulaglutide 0.75 mg
Nausea
5%
insulin glargine
Source sentences
Summary
Dulaglutide was associated with higher rates of nausea (20% [38 of 192] with dulaglutide 1·5 mg and 14% [27 of 190] with 0·75 mg, vs 5% [nine of 194] with insulin glargine)
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomly assigned (1:1:1) by use of a computer-generated random sequence with an interactive response system to once-weekly injectable dulaglutide 1·5 mg, once-weekly dulaglutide 0·75 mg, or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks.
Report a problemFND-2991002412
14HumanRandomized controlled trialSafety outcome
In patients with T2D and kidney disease, diarrhoea was more frequent with dulaglutide 0.75 mg than insulin glargine.
In plain wordsIn patients with T2D and kidney disease, diarrhoea was more frequent with dulaglutide 0.75 mg than insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseDiarrhoea
Study
n = 190
Comparator
Insulin glargine
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.75 mg weeklyAs given in this study (human).
Measurements
Diarrhoea
16%
dulaglutide 0.75 mg
Diarrhoea
7%
insulin glargine
Source sentences
Summary
and diarrhoea (17% [33 of 192] with dulaglutide 1·5 mg and 16% [30 of 190] with 0·75 mg, vs 7% [14 of 194] with insulin glargine)
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomly assigned (1:1:1) by use of a computer-generated random sequence with an interactive response system to once-weekly injectable dulaglutide 1·5 mg, once-weekly dulaglutide 0·75 mg, or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks.
Report a problemFND-2991002414
15HumanRandomized controlled trialSafety outcome
In patients with T2D and kidney disease, symptomatic hypoglycaemia rates were lower with dulaglutide 0.75 mg than insulin glargine.
In plain wordsIn patients with T2D and kidney disease, low-blood-sugar rates were lower with dulaglutide 0.75 mg than insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseSymptomatic hypoglycaemia
Study
n = 190
Comparator
Insulin glargine
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.75 mg weeklyAs given in this study (human).
Measurements
Symptomatic hypoglycaemia
4.3 events per patient per year
dulaglutide 0.75 mg
Symptomatic hypoglycaemia
9.6 events per patient per year
insulin glargine
Source sentences
Summary
and lower rates of symptomatic hypoglycaemia (4·4 events per patient per year with dulaglutide 1·5 mg and 4·3 with dulaglutide 0·75 mg, vs 9·6 with insulin glargine).
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomly assigned (1:1:1) by use of a computer-generated random sequence with an interactive response system to once-weekly injectable dulaglutide 1·5 mg, once-weekly dulaglutide 0·75 mg, or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks.
Report a problemFND-2991002416
16HumanRandomized controlled trialSafety outcome
In patients with T2D and kidney disease, end-stage renal disease occurred in 7% with dulaglutide 0.75 mg versus 8% with insulin glargine.
In plain wordsIn patients with T2D and kidney disease, end-stage renal disease occurred in 7% with dulaglutide 0.75 mg versus 8% with insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedEnd-stage renal disease
Study
n = 190
Comparator
Insulin glargine
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.75 mg weeklyAs given in this study (human).
Measurements
End-stage renal disease
7%
dulaglutide 0.75 mg
End-stage renal disease
8%
insulin glargine
Source sentences
Summary
End-stage renal disease occurred in 38 participants: eight (4%) of 192 with dulaglutide 1·5 mg, 14 (7%) of 190 with dulaglutide 0·75 mg, and 16 (8%) of 194 with insulin glargine.
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomly assigned (1:1:1) by use of a computer-generated random sequence with an interactive response system to once-weekly injectable dulaglutide 1·5 mg, once-weekly dulaglutide 0·75 mg, or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks.
Report a problemFND-2991002418

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

17HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In patients with T2D and kidney disease, HbA1c lowering persisted through 52 weeks in both dulaglutide groups and the insulin glargine group.
In plain wordsIn patients with T2D and kidney disease, HbA1c remained below baseline with both dulaglutide doses and insulin glargine through 52 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change at 52 weeks
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c change
−1.1%
dulaglutide 1.5 mg, 52 weeks
HbA1c change
−1.1%
dulaglutide 0.75 mg, 52 weeks
HbA1c change
−1%
insulin glargine, 52 weeks
Source sentences
Summary
HbA_1c-lowering effects persisted to 52 weeks (LSM -1·1% [SE 0·1] with dulaglutide 1·5 mg; -1·1% [0·1] with dulaglutide 0·75 mg; -1·0% [0·1] with insulin glargine).
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomly assigned (1:1:1) by use of a computer-generated random sequence with an interactive response system to once-weekly injectable dulaglutide 1·5 mg, once-weekly dulaglutide 0·75 mg, or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2991002403

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01621178

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Eli Lilly and Companyn = 577Jul 2012 to Dec 2016

Type 2 Diabetes · Chronic Kidney Disease

Trial page ClinicalTrials.govUpdated 19 Sept 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.